Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases
|
By LabMedica International staff writers Posted on 20 Apr 2021 |

Illustration
Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade. Additionally, PCR advances, fulfillment of the human genome project, and expanding R&D will increase the utilization of biomarker profiling for sickness diagnostics, thus further driving market growth.
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
Latest Industry News
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
- Partnership Aims to Improve Transplant Monitoring Across Care Continuum
- QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
- Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies
- Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Open-Source Consortium Aims to Standardize Digital Pathology Workflows
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
- Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean
- Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
- GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026
- Global Framework Integrates Digital Pathology for Companion Diagnostic Development
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Blood Test Reveals Hidden Pancreatic Cancer After Treatment
Pancreatic cancer often returns even after chemotherapy and surgery, while microscopic disease can remain difficult to detect during surveillance. Standard imaging and broad-panel liquid biopsy tests may... Read more
Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that rapidly impairs motor function and shortens survival, creating sustained demand for multidisciplinary care.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more




.jpg)



